Member Info for RayPointer

Hi Cleaner

The connection is the Seagen mAb SEA-CD40. Scancell added Avidimab to this mAb in order to assess whether this would make it more effective.

This was then presented as a poster at a conference (somewhere in Germany I think from memory). I also seem to remember that the poster generated a fair amount of interest at the time.

It also points to the possibility that Seagen was one of the unnamed companies having an research agreement with Scancell for the Glymab platform.

https://scancell.co.uk/wp-content/uploads/2024/10/pegs-avidimab-2022-poster.pdf

Yes Luckybob.

In the case of paternostpauper, it is quite uncanny how his rhetoric matches that of Mark Eccleston. Perhaps they are twins 😂

Https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/clinical-trial-regulations-reform/guidance-on-changes-to-the-clinical-trials-regulations/the-approvals-process-for-clinical-trials/the-approvals-process-for-applications/

The above link describes the MHRA approval process. Looks OK, until you add on the possible extensions to the timelines should it be decided that outside expertise is required to make a decision.

This involvement of outside expertise can add a whopping 150 calendar days to the process.

"If independent expert advice is sought:

during the initial review stage for your application, the 30 day timeframe may be extended by up to an additional 90 calendar days (bringing the maximum timeframe to 120 calendar days)

following a response to a request for further information being received, the 10 day timeframe may be extended by up to an additional 30 calendar days (bringing the maximum timeframe to 40 calendar days)

following a response to a request for further information being received and an advanced therapy medicinal product (ATMP) is involved in the trial, the 10 day timeframe may be extended by up to an additional 60 calendar days (bringing the maximum time frame to 70 calendar days)"

This brings the maximum number of calendar days for a decision to 257 days i.e. 8 and a half months. We don't know yet if, in Scancell's case, that the maximum of 257 calendar days will be reached but it is tending to look that way. IMO this is ridiculous for a phase 3 trial when a wealth of data was already available from a very successful phase 2 trial of over 100 patients.

As a postscript, I asked Gemini 3 questions this morning

Q1 "is GEN1079 actually SC129?"

The answer contained:

"As of June 2026, there is no official public confirmation or direct statement from either Genmab or Scancell explicitly confirming that GEN1079 is SC129. However, within the biotech industry and among market analysts, there is an overwhelming consensus that GEN1079 is almost certainly SC129 (the anti-glycan antibody targeting sialyl-di-Lewis$^a$ that Genmab licensed from Scancell back in October 2022)."

Q2 "Have the market analysts actually confirmed that GEN1079 is actually SC129?"

Included in the answer:

"No. To be perfectly direct: neither market analysts nor the companies themselves have officially confirmed that GEN1079 is SC129. What exists right now is a highly educated "guess"—a strong circumstantial case built by the biotech investment community, but it remains unconfirmed."

Q3 "In this case who exactly are the biotech investment community?"

Included in the answer:

"This specific rumor caught fire on financial forums like the London South East (LSE) Scancell Share Chat."

Anybody care to start another rumour that Scancell is being bought by a Major Pharma for £8 a share? 😂

"If in doubt, use the free Hallucination Detector."

But does the "Hallucination Detector" hallucinate?

In other words Gemini frequently hallucinates! 😂

Gemini says:

"Target: Though its exact molecular targets are closely guarded, industry data indicates that GEN1079 is derived from SC129, an anti-glycan monoclonal antibody (Glymab®) originally developed by Scancell and subsequently licensed to Genmab."

But

"51.4%

Of Gemini's high-confidence answers were contradicted by another model "

https://suprmind.ai/hub/ai-hallucination-rates-and-benchmarks/

So, next Tuesday night we meet at the Golden Cross (soon to be renamed as the "Citrullinated Epitope Arms").

A good rendition of "Scancell's coming home" and some very puzzled locals joining in for the free beer.

C11

Oh, that might be tempting fate, relating Scancell's chance of success with that of England winning the World Cup. 😂

Come on Notpot, Pater and Uxm give us doubters some concrete evidence of the "Massive year ahead".

Perhaps in the form of research articles published by Valirx staff.

In other words, give the BB something to debate in which that something is not just rhetoric.

But will it be a Ferrari or a Skoda?

https://www.autogott.de/coupleimg/ferrari-sf90-coupe_vs_skoda-octavia-combi.jpg

Hi Chester

My recollection is that Phil stated that the reason for delaying the Modi1 results was that big pharma often easily lose interest when confronted with multiple trial updates. So, his way of countering this, was to delay the next update until such a time that enough data is collected to have a big impact. The ideal would be to produce as much interest in Modi1 as they have seen in the Scope trial. We shouldn't rule out that the impact of the Modi1 results could actually be bigger than that of the Scope trial. Richard Goodfellow once said that, in the early days of Moditope, they were getting unsolicited interest. This also is backed up by the quality of the team members of Scancell's entry to the CRUK grand challenge.

IMO, there isn't an NDA stopping the publication of the Modi1 results.

Here is Wild's hat 😂

https://www.columbia.edu/~jpl2131/lunch/tacohat.jpg

Actually Lindy has previously stated that big pharma don't actually go looking for hidden gems ripe for takeover.

This would explain why Scancell, up until recently, have been attending all the major conferences to promote the Scope trial results.

Exactly Crusty, SpaceX is full of risk and hyped to oblivion. It's bound to pop sooner or later.

Meanwhile, Scancell have a good supply of bubble-gum still in wrappers.

Maybe the latest pump and dump has started. It's very annoying that nobody informed us😒

Elon is faking an IPO to buy Scancell shares on the cheap - confirmed by AI

A musk go to share

My opinion only, but I would say that both Phil and Lindy would not want an outright sale of the company at present. There is so much work still to do to realise the potential of Moditope and also the Glymabs that they choose to keep in house.

You may be right EE

https://scancell.co.uk/wp-content/uploads/2024/10/glymab_worldadclondon_final_ms_mnv.pdf